Huons Presents Preclinical Results for Fibrostenotic Crohn's Disease Treatment

Inhibition of ECM cross-linking and intestinal fibrosis
"Developing it as a first-in-class drug"

Huons said on October 20 that it had presented poster findings from preclinical studies of HUC1A-626, a selective TG2 inhibitor, at UEG Week 2026, the annual scientific meeting of United European Gastroenterology, held in Barcelona, Spain, from October 17 to 20 (local time).

HUC1A-626 is a compound Huons is developing to treat fibrostenotic Crohn's disease (FSCD). Biologics used to treat FSCD are effective at controlling inflammation, but have limitations in suppressing or reversing fibrotic lesions that have already developed.

Huons researchers present a poster on preclinical study findings for HUC1A-626, a candidate treatment for fibrostenotic Crohn's disease, at UEG Week 2026, the annual scientific meeting of the United European Gastroenterology, held in Barcelona, Spain, on the 18th (local time). Huons

TG2 is an enzyme that abnormally cross-links extracellular matrix (ECM) proteins and prevents accumulated matrix from breaking down, acting like an adhesive that hardens tissue. Huons researchers identified HUC1A-626, an oral TG2 inhibitor designed to act locally in the intestines, and evaluated its antifibrotic effects from multiple angles in cell and animal models.

HUC1A-626 showed high inhibitory potency and selectivity against TG2. In experiments using human colon-derived fibroblasts, researchers confirmed antifibrotic effects across multiple pathways through TG2 inhibition. In animal models, fibrotic lesions and insoluble collagen levels decreased, and antifibrotic effects were observed in both histological and quantitative analyses.

Based on these findings, Huons plans to present a new treatment strategy that differentiates the drug from existing treatments and targets the underlying cause of the disease.

Park Kyung-mi, Huons' Executive Vice President and Head of Research and Development, said, "We will develop it as a first-in-class innovative drug that breaks the cycle of fibrosis that continues even after inflammation subsides, offering a fundamental solution to patients with fibrostenotic Crohn's disease."

This content was produced with the assistance of AI translation services.